Cardiology News
♦ New guidelines for diabetes and cardiovascular disease. (15/09/2019)
♦ Praluent (alirocumab) reduces mortality for atherosclerotic cardiovascular diseases (ASCVD). (23/04/2019)
♦ Optimizer Smart – an innovative device for the treatment of chronic cardiac insufficiency. (08/04/2019)
♦ A new technology could be a lifesaver for individuals with heart failure awaiting transplant
⇐ All news
⇐ Leading cardiologists and cardiac surgeons
DEAR SITE VISITORS, PLEASE NOTE!
ResultMed provides medical treatment organization and coordination services for foreign patients only.
!מבקרים באתר היקרים, אנא שימו לב
.אנחנו חברה תיירות מרפא. אנו נותנים שרות פרטי לתיירים בלבד
For foreign patients:
+ 972 54 803 45 32
New guidelines for diabetes and cardiovascular disease
Two large European organizations – the European Cardiology Society (ESC) in collaboration with the European Association for the Study of Diabetes (EASD) – have released a new guidelines for patients with diabetes or prediabetic diseases related to the use of new drugs and the prevention of cardiovascular disease (CVD). The recommendations were presented at ESC Congress, and were also published in the European Heart Journal.
Praluent (alirocumab) reduces mortality for atherosclerotic cardiovascular diseases (ASCVD)
Praluent is the only PCSK9- inhibitor approved in EU. The collected data indicate a mortality decrease in cardiovascular diseases.
Optimizer Smart – breakthrough device for the treatment of cardiac insufficiency
On March 21, 2019, the FDA approved an innovative device – Smart Optimizer System for treating patients with moderate to severe chronic cardiac insufficiency (CHF) with CCM technology.